We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
13/1/2021 11:32 | It will pop soon, and then gap up on EU approval | trotterstrading | |
13/1/2021 11:24 | It's the culture we live in. Impatiently selling for £500 and the pi's wonder why they never make any money. It will hit 75p again sooner than you think. | aimmafia | |
13/1/2021 10:36 | The price is not going back to even 75p. There must be a large seller still in the background. I cannot believe PI's that bought in at placing price would sell up for a paltry 2 to 3 pence rise. Even institutions have a long term outlook so they too would be unlikely.So in conclusion it must be a large seller or another institution buying them up and the mms are holding the price until either her/ both outcomes have been resolved | glasswala | |
13/1/2021 10:19 | What wally just sold at 61 haha | aimmafia | |
13/1/2021 10:16 | Hmmm to you too. | babbler | |
13/1/2021 10:16 | It's happening guys..... this is going to absolutely melt the stock market soon | aimmafia | |
13/1/2021 10:09 | Hello hello. | babbler | |
12/1/2021 18:19 | New Vox Market report; hxxps://www.voxmarke A brief summary; "Chronocort, filed with EMA, BREXIT now with UK authority. Made clear to market that they have filed with UK market. Still waiting for EU approval, balance of probability is they will get approval, this will be a big share price event. Cortisone is a well-known drug, Diurnal specialise in better delivery to avoid spikes and troughs. Their delivery method is better. What’s good is they are working with a safe drug, it is just about the better delivery. They filed for approval previously, it failed on some data, it was poured over with the company and regulators and they agreed the application should be submitted none the less, which is very encouraging – a very strong sign the regulator wants this to be approved. Approval will be a step change in valuation, author is holder, could be multiples of current valuation." | hunsen | |
12/1/2021 15:54 | ps and now the 61p bid..same as you can buy ?? what is it with this stock lol | tarlok | |
12/1/2021 15:33 | SC Have you seen the staff here ? 😞😔 | simon_64 | |
12/1/2021 15:23 | I used to think the same at my place of work but it turned out to be the boss shagging the secretary before anyone else got in. C'est la vie. | small crow | |
12/1/2021 15:00 | Not really surprised at the drop here, as it has always been quite leaky, if we hadn’t had the raise would have been sat at a £1 now IMHO. Happy to hold here so much news to come , I always take a glance over to their labs when I walk the dogs up Heath Park they are still working solidly, as I am up the park at 8.00 ish and the lights are on. | simon_64 | |
12/1/2021 14:57 | Extremely disappointed to be down after such good news 2 days in a row. Couldn't make it up | aimmafia | |
12/1/2021 10:31 | 62 are sells. Everything above buys | aimmafia | |
12/1/2021 10:06 | AimMafia you will find today is mostly buying. It appears sells but are not. | frrinvest | |
12/1/2021 09:31 | They stated initial interest was strong in Nov sales were to follow.. ALKINDI SPRINKLE Eton anticipates having commercial availability of ALKINDI SPRINKLE by the end of November. The company’s ALKINDI SPRINKLE sales representatives have been hired, fully trained, and have begun engaging with pediatric endocrinologists. Initial interest from physicians, caregivers, and patients has been very strong and Eton expects the product to exceed the company’s original sales forecast for 2021. | bad gateway | |
12/1/2021 09:24 | Didn't Eton say initial sales exceeded expectations? | babbler | |
12/1/2021 09:17 | News on sales would be good esp in the U.S. Do wonder if the problem is lack of sales due to the hospitals being empty and health services generally shut down due to covid? Only answer i have for the insti's not having bought the stock up? | bad gateway | |
12/1/2021 09:11 | I am in total disbelief people are selling and not buying into this.... once this pops it's going to go big | aimmafia | |
12/1/2021 07:48 | I cant believe we are In The 60s still..... the ducks are well and truely lined up | aimmafia | |
12/1/2021 07:11 | Fantastic news. DNL is truly becoming world class Pharma. | frrinvest | |
12/1/2021 07:08 | Taken from Today's RNS - basically hold for 90 days and you will be rewarded massively! We are pleased to announce one of the first submissions of a Marketing Authorisation Application to the MHRA via the "in flight" process. Chronocort(R) remains on track to be approved by the EMA during Q1 2021, with the MHRA approval also now expected during this period. We look forward to the potential launch of our second product in Great Britain and European Economic Area as we continue to build our commercial portfolio and drive towards becoming a world-leading specialty endocrinology business. There is a significant need for new therapies to improve outcomes for adult patients with CAH, which still results in increased morbidity and mortality worldwide. We believe that Chronocort(R) , together with our paediatric product Alkindi(R) , has the potential to provide new treatment options for CAH patients throughout their lives." | aimmafia | |
11/1/2021 18:58 | It will have to at some point | l0ngterm |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions